Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Family Medicine
Disease Category: Cancer Treatment
Location: United States, CA
An Open Label, Multi-Center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the Continued Treatment of Patients in the United States who are Currently Benefiting or who have Benefited from Gefitinib Treatment
You have been asked to participate in this research study because drug Gefitinib (IRESSA™) will be removed from the list of available AstraZeneca medicines through your current program by September 30, 2011. However, as a patient who currently receives gefitinib, you will have the opportunity to enrol in a new research study called a Clinical Access Program.
This Clinical Access Program has been set up to make sure those patients in the United States who have been receiving and benefiting from gefitinib will have the option of continuing to receive gefitinib after September 30, 2011. Through this study, you can continue to receive gefitinib as long as your doctor continues to order it for you.
Patient Inclusion/Exclusion Criteria:
- See http://clinicaltrials.coh.org for additional information.
City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)
Research Center Information: City of Hope
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these